key: cord-0949025-m52rs514
authors: Jin, Haoli; Reed, James C.; Liu, Sean T.H.; Ho, Hsi-en; Lopes, Joao Pedro; Ramsey, Nicole B.; Waqar, Omar; Rahman, Farah; Aberg, Judith A.; Bouvier, Nicole; Cunningham-Rundles, Charlotte; Lin, Hung-Mo; Abrams-downey, Alexandra; Cascetta, Krystal P.; Glatt, Aaron E.; Koshy, Sanjana C.; Kojic, Erna; Mazo, Dana S.; Perlman, David; Rudolph, Steven; Steinberg, Jason; Schneider, Thomas; Baine, Ian; Wajnberg, Ania; Gumprecht, Jeffrey P.; Rodriguez, Denise; Sanky, Charles; Dupper, Amy; Altman, Deena R.; Krammer, Florian; Mendu, Damodara Rao; Firpo-Betancourt, Adolfo; Cordon-Cardo, Carlos; Jhang, Jeffrey S.; Arinsberg, Suzanne A.; Reich, David L.; Bouvier, Nicole M.
title: Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma
date: 2020-09-15
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.08.059
sha: cb55f246946153da843c547e31b221212eb00183
doc_id: 949025
cord_uid: m52rs514

nan

Clinical Implications: 50 We describe three XLA patients with COVID-19 who failed supportive treatment but 51 recovered after receiving convalescent plasma.

The Coronavirus Disease 2019 (COVID-19) pandemic has presented a global challenge.

The pathogenesis of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) 55 infection is complex and effective therapy is currently lacking. Convalescent plasma 56 transfusion is safe and under investigation for effectiveness. 1-6 57 58

We report three hospitalized patients (Supplementary Table E1 and Figure E1 ) with X- (Table 1) .

In the first two weeks of hospitalization, he received a red blood cell transfusion, broad-76 spectrum antibiotics, oxygen supplementation and albuterol treatments, and a dose of 

Deployment of 181 convalescent plasma for the prevention and treatment of COVID-19

Early 184 safety indicators of COVID-19 convalescent plasma in 5,000 patients

Treatment of 5 Critically Ill Patients 186 With COVID-19 With Convalescent Plasma

Effectiveness of convalescent plasma 188 therapy in severe COVID-19 patients

Treatment with convalescent plasma 190 for COVID-19 patients in Wuhan

Convalescent 193 plasma treatment of severe COVID-19: A matched control study

A possible role 195 for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Two X-linked 198 agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

An 201 inflammatory cytokine signature predicts COVID-19 severity and survival

2 (B) and 3 (C), respectively, showing

Pediatric ranges are given for patient 1 and adult ranges for patients 2 and 3. ‡ Abbreviations are 222 WBC (White Blood Cell Count

*These values are 225 from * = 1 day prior to discharge and # = 3 days prior to discharge. $ A value of more than 10 226 times this is the recorded peak however it does fit with the remainder of the patient's clinical 227 data. α, = at diagnosis. δ = before IVIG, later increased to 1,021 on readmission. Bolded 228 numbers are abnormal lab values. ‡ For COVID-19 patients aged 10-40 years at our institution, the first to third quartile ranges are 229 0.1-0.7 pg/mL for IL-1β